Prostate Cell News Volume 10.36 | Sep 27 2019

TOP STORY

Identification of the PTEN-ARID4B-PI3K Pathway Reveals the Dependency on ARID4B by PTEN-Deficient Prostate Cancer

Scientists report a PTEN-ARID4B-PI3K axis in which PTEN inhibited expression of ARID4B, while ARID4B was a transcriptional activator of the PI3K subunit genes PIK3CA and PIK3R2 that were crucial for activation of the PI3K/AKT pathway. [Nat Commun] Full Article | Press Release

(Ranked by impact factor of the journal)

High-Fat Diet Fuels Prostate Cancer Progression by Rewiring the Metabolome and Amplifying the MYC Program

Researchers demonstrated in a murine prostate cancer model that high-fat diet enhanced the MYC transcriptional program through metabolic alterations that favored histone H4K20 hypomethylation at the promoter regions of MYC regulated genes, leading to increased cellular proliferation and tumor burden. [Nat Commun] Full Article

Primary Prostate Cancer Educates Bone Stroma through Exosomal Pyruvate Kinase M2 to Promote Bone Metastasis

Investigators identified exosome-mediated transfer of pyruvate kinase M2 from prostate cancer cells into bone marrow stromal cells as a novel mechanism through which primary tumor-derived exosomes promote premetastatic niche formation. [J Exp Med] Abstract | Graphical Abstract

Cross Linked Polyphenol-Based Drug Nano-Self Assemblies Engineered to Blockade Prostate Cancer Senescence

In vivo and ex vivo imaging analysis demonstrated the tumor targeting behavior of tannic acid-docetaxel self-assemblies (DSAs) in mice bearing PC-3 xenograft tumors. The anti-senescence and anti-cancer activity of DSAs was further shown in vivo by inhibiting TGFβR1 proteins and regressed tumor growth through apoptotic induction in PC-3 xenograft mouse model. [ACS Appl Mater Interfaces] Abstract

A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

A novel analog of 2-(((3,5-dimethylisoxazol-4-yl)methyl)thio)-1-(4-(2,3-dimethylphenyl)piperazin-1-yl)ethan-1-one, JJ-450, was investigated with evidence for its direct and specific inhibition of AR transcriptional activity via a pulldown assay and RNA-seq analysis, PSA-based luciferase, qPCR, and ChIP assays and xenograft tumor model 22Rv1. [Mol Cancer Ther] Abstract

Reversal of the Warburg Phenomenon in Chemoprevention of Prostate Cancer by Sulforaphane

The authors utilized human prostate cancer cell lines, two different transgenic mouse models, and plasma specimens from a clinical study to explore the glycolysis inhibition potential of sulforaphane. [Carcinogenesis] Abstract

The BRCA2 Mutation Status Shapes the Immune Phenotype of Prostate Cancer

Scientists characterized the immune infiltrate of eight BRCA2-mutated tumors in comparison with eight BRCA1/2 wild-type patients by T-cell receptor sequencing and immunohistochemistry for CD45, CD4, CD8, FOXP3, and CD163. [Cancer Immunol Immunother] Abstract

Up Regulation of Rho-Associated Coiled-Coil Containing Kinase1 (ROCK1) Is Associated with Genetic Instability and Poor Prognosis in Prostate Cancer

A weak ROCK1 staining was found in >90% of normal, and cancerous prostate tissues, but was generally stronger in cancer cells as compared to adjacent normal glands. In cancer, ROCK1 staining was considered weak, moderate, and strong in 22%, 53%, and 18% of cases respectively. [Aging (Albany NY)] Full Article

CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions

Researchers found that androgen withdrawal promoted the growth of CPT1A over-expressing tumors while it decreased the growth of CPT1A under-expressing tumors, increasing their sensitivity to enzalutamide. [Cells] Full Article | Graphical Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Estrogen Receptors in Epithelial-Mesenchymal Transition of Prostate Cancer

The authors discuss the findings on the role of estrogen/estrogen receptor axis in epithelial versus mesenchymal transition of prostate cancer cells. [Cancers] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

City of Hope Opens Chimeric Antigen Receptor (CAR) T Cell Trial for Advanced Prostate Cancer

City of Hope has opened and is treating the first patients in its CAR T cell trial for prostate cancer that has spread to other parts of the body. The trial uses a CAR T cell – also developed at City of Hope – that targets the prostate stem cell antigen in prostate cancer. [City of Hope] Press Release

Anixa Biosciences Announces University of Maryland School of Medicine to Join Cchek™ Prostate Cancer Study

Anixa Biosciences, Inc. announced that Mohummad Siddiqui, MD, Associate Professor of Surgery at the University of Maryland School of Medicine has joined its ongoing prostate cancer Cchek™ study. [Anixa Biosciences, Inc.] Press Release

The Prostate Cancer Foundation Announced a Collaborative Grants Program in Prostate Cancer Research

The Prostate Cancer Foundation announced a collaboration with Pfizer Global Medical Grants to fund approximately $2 million in research grants through a Competitive Research Grants Program, which is focused on investigating talazoparib, a poly (ADP-ribose) polymerase inhibitor, in prostate cancer. [Prostate Cancer Foundation] Press Release

U-M, Karmanos Receive $9.2M Grant for Prostate Cancer Research

The University of Michigan (U-M) Rogel Cancer Center and the Barbara Ann Karmanos Cancer Institute at Wayne State University have received a prestigious $9.2 million grant from the National Cancer Institute. [University of Michigan] Press Release

NIH Reveals Its Formula for Tracking Foreign Influences

The US National Institutes of Health (NIH) thinks it may have figured out how China’s foreign talents recruitment program is undermining its system for making awards and ensuring ethical behavior by its grantees. [ScienceInsider] Editorial

Situation Improves Slightly for U Alaska, Major Changes Ahead

Funding cuts provoke concerns about job losses, cancelled research programs, and closed departments. [The Scientist] Editorial

NEW AACR International Conference on Molecular Targets and Cancer Therapeutics
October 26-30, 2019
Boston, Massachusetts, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellowship – Prostate Cancer (Weill Cornell Medicine)

NEW Postdoctoral Fellowship – Molecular Mechanisms of Androgen Synthesis (Cleveland Clinic)

Postdoctoral Researcher – Molecular Basis of Cancer (Max Planck Institute for Molecular Genetics)

Postdoctoral Associate – Prostate and Breast Cancer (Baylor College of Medicine)

Two Postdoctoral Fellows – Prostate or Brain Cancer (Rutgers Cancer Institute of New Jersey)

Postdoctoral Research Scientist – Prostate and Bladder Cancer (Columbia University Medical Center)

Computational Postdoctoral Fellow – Single-Cell Epigenomics and 3D Genomes in Cancer (Princess Margaret Cancer Centre)

Senior Research Assistant – Genitourinary Oncology (MD Anderson Cancer Center)

Professor/Associate Professor – Prostate Cancer (Uniformed Services University of the Health Sciences)

Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.